{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:48:27Z","timestamp":1790642907868,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Apellis Pharmaceuticals"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ajo.2019.03.005","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T11:52:40Z","timestamp":1552477960000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Anti\u2013Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions"],"prefix":"10.1016","volume":"204","author":[{"given":"Thomas J.","family":"Wubben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott H.","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Peairs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannis M.","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Zacks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C.","family":"Steinle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria H.","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ajo.2019.03.005_bib1","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group","volume":"88","year":"1981","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.005_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2016.12.005","article-title":"Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab","volume":"124","author":"Bressler","year":"2017","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.ajo.2019.03.005_bib3","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ajo.2019.03.005_bib4","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0161-6420(91)32085-2","article-title":"Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation","volume":"98","author":"Vander","year":"1991","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.005_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0161-6420(85)34059-9","article-title":"Treatment of proliferative diabetic retinopathy. Long-term results of argon laser photocoagulation","volume":"92","author":"Little","year":"1985","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.005_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0021-5155(99)00006-4","article-title":"Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation","volume":"43","author":"Dogru","year":"1999","journal-title":"Jpn J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2019.03.005_bib7","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0161-6420(03)00579-7","article-title":"The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study","volume":"110","author":"Chew","year":"2003","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.005_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0161-6420(91)32326-1","article-title":"Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute\u2019s patients participating in the diabetic retinopathy study","volume":"98","author":"Blankenship","year":"1991","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2019.03.005_bib9","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2019.03.005_bib10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"130","author":"Ip","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.005_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ophtha.2014.08.048","article-title":"Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy","volume":"122","author":"Ip","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2019.03.005_bib12","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ophtha.2014.07.020","article-title":"Gaps in receipt of regular eye examinations among medicare beneficiaries diagnosed with diabetes or chronic eye diseases","volume":"121","author":"Sloan","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2019.03.005_bib13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections","volume":"125","author":"Obeid","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.005_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation vs intravitreal anti-vascular endothelial growth factor","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2019.03.005_bib15","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/IAE.0000000000001358","article-title":"Microbiologic spectrum and visual outcomes of acute-onset endophthalmitis undergoing therapeutic pars plana vitrectomy","volume":"37","author":"Sridhar","year":"2017","journal-title":"Retina"},{"issue":"10085","key":"10.1016\/j.ajo.2019.03.005_bib16","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajo.2019.03.005_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jdiacomp.2014.11.005","article-title":"Diabetes mellitus and infection: an evaluation of hospital utilization and management costs in the United States","volume":"29","author":"Korbel","year":"2015","journal-title":"J Diabetes Complicat"},{"issue":"1","key":"10.1016\/j.ajo.2019.03.005_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ophtha.2018.08.001","article-title":"Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy","volume":"126","author":"Sun","year":"2019","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2019.03.005_bib19","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","article-title":"Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice","volume":"38","author":"Weiss","year":"2018","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2019.03.005_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2019.03.005_bib21","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2019.03.005_bib22","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.ophtha.2015.08.006","article-title":"Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials","volume":"122","author":"Boyer","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.03.005_bib23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/IAE.0000000000002422","article-title":"Anti-VEGF therapy can improve diabetic retinopathy score without change in retinal perfusion","volume":"39","author":"Bonnin","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2019.03.005_bib24","doi-asserted-by":"crossref","first-page":"629452","DOI":"10.1155\/2012\/629452","article-title":"Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy","volume":"2012","author":"Gologorsky","year":"2012","journal-title":"Mediators Inflamm"},{"issue":"9","key":"10.1016\/j.ajo.2019.03.005_bib25","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.ophtha.2016.05.037","article-title":"Cost evaluation of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy","volume":"123","author":"Lin","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2019.03.005_bib26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2016.08.008","article-title":"Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: patient-centered outcomes from a randomized clinical trial","volume":"170","author":"Beaulieu","year":"2016","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419301035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419301035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:41:30Z","timestamp":1762080090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939419301035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":26,"alternative-id":["S0002939419301035"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2019.03.005","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti\u2013Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2019.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}